June 2015 Br J Cardiol 2015;22:68
Dr David Mantle
Dear Sirs, We wish to comment on two recent clinical trial studies relating to the use of supplementary coenzyme Q10 (CoQ10) for the treatment and prevention of cardiovascular disease. In the first randomised controlled trial, the Q-Symbio study by Mortensen et al,1 oral supplementation with CoQ10 (300 mg/day for two years, as an adjuvant to conventional medication) in 420 patients with chronic heart failure (New York Heart Association class III or IV) reduced the risk of cardiac related mortality by 47% compared to placebo. In the second randomised controlled trial, the KiSel-10 study by Alehagen et al,2 oral supplementation with CoQ10 (200
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits